New York, NY – In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) activate immune system cells linked to inflammatory bowel disease (IBD) and other inflammatory diseases. This discovery, reported in Proceedings of the National Academy...
Latest News
New York, NY — Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance. The study, published in the October 30 online issue of Cell [DOI: 10.1016/j.cell.2024.10.006],...
New York, NY — Recent developments in cancer research have highlighted the vital role of the immune system, particularly in the notable successes of cancer immunotherapy. Now, a paradigm-shifting study led by researchers at the Icahn School of Medicine at Mount Sinai in New York in collaboration with the University of...
The classic symptoms of Parkinson’s disease involve tremor, stiffness and slow movements. Over the last decade, neurologists have been paying greater attention to non-motor symptoms, such as digestive and sleep problems, loss of sense of smell and depression. A genetically engineered mouse reproduces many of the non-motor symptoms associated with...
Baltimore, Maryland – A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences. In the...
Twenty-four parliamentarians across party lines have approached Union health and family welfare minister Mansukh Mandaviya, underlining the need for sustainable funding support for certain diseases under the National Policy for Rare Diseases 2021.
Minimal residual disease (MRD) assessment can be used to guide treatment discontinuation in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), according to phase 2 results published in the Journal of Clinical Oncology. The phase 2 CAPTIVATE trial (ClinicalTrials.gov Identifier: NCT02910583) was designed to test MRD-guided treatment discontinuation after first-line ibrutinib plus...
GHENT, Belgium — MRM Health, a clinical-stage biopharmaceutical company, announced today that it has received regulatory and ethics committee approval to start an observational, cross-sectional clinical trial to study the role of the small intestinal microbiome in Parkinson’s Disease (PD) and to identify PD-specific microbial and metabolic fingerprints in small...
London, UK – The research, published in Science Translational Medicine, found that messenger RNA (mRNA) could be used to correct a rare liver genetic disease known as argininosuccinic aciduria in a mouse model of the disease. Argininosuccinic aciduria is an inherited metabolic disorder that affects how the body breaks down...
FRANKFURT, Germany – Each year, several thousand women in Germany die from ovarian cancer. In many cases, the disease is only detected when it is very advanced and metastases have already formed – usually in the intestines, abdomen or lymph nodes. At such a late stage, only 20 to 30...